Myotonic Dystrophy Type 1 Clinical Trials

40 clinical trials for Myotonic Dystrophy Type 1 across international registries, including 15 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 — RECRUITING · PHASE3
• A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I — RECRUITING · PHASE2
• Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension — RECRUITING
• Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 — RECRUITING · PHASE3
• Brain Structure and Clinical Endpoints in Myotonic Dystrophy Type 2 — RECRUITING
• Personalized Training for People With Rare Neuromuscular Disorders — RECRUITING · NA
• A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) — RECRUITING · PHASE1
• Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy — RECRUITING
• Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 — RECRUITING · PHASE1
• Remote Assessments and Genetic Determinants of Myotonic Dystrophy — RECRUITING
• The Spanish National Registry for Myotonic Dystrophy Type 1 — RECRUITING
• Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy — RECRUITING
• Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry — RECRUITING
• A Registered Observational Cohort Study of Myotonic Dystrophy Type 1 — RECRUITING
• Pelvic Floor Muscle Training for Women with Myotonic Dystrophy — RECRUITING · NA
• A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1 — TERMINATED · PHASE3
• A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1 — TERMINATED · PHASE3
• A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of Intravenous Administration of ATX-01 In Male and Female Participants aged 18 to 64 with Classic Myotonic Dystrophy Type 1 (DM1) — TERMINATED · PHASE1
• Music Intervention for Brain-Heart Disease in Myotonic Dystrophy Type 1 (DM1) — ACTIVE_NOT_RECRUITING · NA
• Virtual Reality-training in Theory of Mind in the Childhood Form of Myotonic Dystrophy Type 1 — COMPLETED · NA
• EVALUATION OF THE EFFICACY AND SAFETY OF METFORMIN IN THE MYOTONIC DYSTROPHY TYPE I (STEINERT’S DISEASE). PHASE III PROSPECTIVE, MULTICENTRE, RANDOMISED, DOUBLE-BLIND CONTROLLED STUDY. — TERMINATED · PHASE3
• A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1 — OTHER · PHASE3
• A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1 — TERMINATED · PHASE2
• Fall Frequency and Factors Affecting Dynamic Balance in Patients With Myotonic Dystrophy Type 1 — ACTIVE_NOT_RECRUITING
• Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients — COMPLETED · PHASE1
• Global Study of Del-desiran for the Treatment of DM1 — ACTIVE_NOT_RECRUITING · PHASE3
• A Remote Physical Activity Program in the Population Suffering from Type 1 Myotonic Dystrophy — ACTIVE_NOT_RECRUITING · NA
• Wheelchair Skills Training for People with ARSACS and DM1 — NOT_YET_RECRUITING · NA
• Technology Assisted Rehabilitation for Upper Limb Function in Myotonic Dystrophy Type 1 — COMPLETED · NA
• A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 — COMPLETED · PHASE1
• Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders — COMPLETED
• Breathlessness Assessment in Adult Patients With Myotonic Dystrophy Type 1 — COMPLETED
• Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 — COMPLETED · PHASE2
• Assessing Clinical Endpoints and Biomarkers in Myotonic Dystrophy Type-1 and Type 2 (ASCEND-DM) — TERMINATED
• Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1 — COMPLETED · PHASE1
• PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study) — COMPLETED
• Brain Involvement in Myotonic Dystrophy Type I: From Functional Neuroimaging to the Impact on Quality of Life — COMPLETED
• Multicenter Observational Study of Myotonic Dystrophy Type 1 — COMPLETED
• Observational Prolonged Trial in Myotonic Dystrophy Type 1 — COMPLETED · NA
• Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy — OTHER

Refine this search